Warren Lockette
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Warren Lockette has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Ryan Woodman
University of California, Davis, CA
3 shared publications Coleman Miller
Wayne State University School of Medicine
2 shared publicationsJeffrey Student
Wayne State University School of Medicine
2 shared publications- Kalev Freeman
University of Vermont
2 shared publications Ryan Woodman
Wayne State University School of Medicine, Detroit, MI, USA
2 shared publicationsAdrian M Sackheim
Department of Emergency Medicine, University of Vermont
1 shared publication
Latest Publications
- Open Access
- 22 July 2026
- Published by Elsevier in Current Problems in Surgery
- Vol. 82
If it is in the adrenal gland, it is not essential (hypertension)
- 22 July 2026
- Published by Elsevier in Current Problems in Surgery
- Vol. 82
Open AccessIf it is in the adrenal gland, it is not essential (hypertension)
- Open Access
The Set Point Is Not Where We Thought: The Primacy of Baroreflex Gain Variability
For decades, cardiovascular physiology has been built on the assumption that arterial barorecep-tors adjust heart rate (HR) to maintain a defined blood pressure set point. We challenge this paradigm fundamentally. Blood pressure and heart rate both change substantially in response to physiological stress and neither returns reliably to a fixed baseline value. This raises the question of whether a higher-order variable, one that remains stable while blood pressure and heart rate reset freely might better represent a truly defended, “set-point” quantity. We hypothesized that instantaneous baroreceptor gain (IBS), expressed as the change in R-R interval per unit change in systolic blood pressure (SBP), has a coefficient of variation (IBS CV) that is invariant across different physiological challenges. If IBS CV is fixed, then ΔHR and ΔSBP must vary proportionally, maintaining a stable gain relationship even as each changes in magnitude. This constraint suggests that blood pressure and heart rate are adjustable outputs that reset freely in response to physiological demand, rather than defended targets in their own right. An invariant IBS CV guarantees that the baroreflex arc behaves consistently and predictably across the full range of physiological states: the brain can rely on a stable gain relationship between blood pressure and heart rate, enabling reliable closed-loop cardiovascular control without having to recalibrate the relationship under every new condition. To test this hypothesis, we had healthy adult volunteers undergo either the cold pressor test or passive orthostatic challenge. Heart rate (HR), systolic blood pressure (SBP), IBS (the regression coefficient of R-R intervals on their respective systolic blood pressures), and the coefficients of variation (CV, i.e. standard deviation ÷ mean value) of each were measured at baseline and during each stress perturbation. During orthostatic challenge, HR rose significantly while SBP fell significantly. Classically, this HR rise is attributed to baroreflex compensation for falling pressure. However, the critical observation is that SBP was not restored to baseline. Instead, it remained substantially reduced while HR stayed persistently elevated and HR CV increased significantly. A system primarily defending a blood pressure set point should augment baroreflex gain and suppress pressure variability; instead mean IBS showed no significant change, SBP CV amplified more than threefold, and IBS CV was unchanged. During the cold pressor test, both HR and SBP rose simultaneously, which is inconsistent with a pressure-defending system that would have suppressed HR in response to the large rise in SBP. IBS CV was also stable across this perturbation while SBP CV amplified dramatically. These findings challenge the classical baroreceptor set-point model and suggest that IBS CV, not blood pressure, is the primary regulated cardiovascular variable.
Open AccessThe Set Point Is Not Where We Thought: The Primacy of Baroreflex Gain Variability
For decades, cardiovascular physiology has been built on the assumption that arterial barorecep-tors adjust heart rate (HR) to maintain a defined blood pressure set point. We challenge this paradigm fundamentally. Blood pressure and heart rate both change substantially in response to physiological stress and neither returns reliably to a fixed baseline value. This raises the question of whether a higher-order variable, one that remains stable while blood pressure and heart rate reset freely might better represent a truly defended, “set-point” quantity. We hypothesized that instantaneous baroreceptor gain (IBS), expressed as the change in R-R interval per unit change in systolic blood pressure (SBP), has a coefficient of variation (IBS CV) that is invariant across different physiological challenges. If IBS CV is fixed, then ΔHR and ΔSBP must vary proportionally, maintaining a stable gain relationship even as each changes in magnitude. This constraint suggests that blood pressure and heart rate are adjustable outputs that reset freely in response to physiological demand, rather than defended targets in their own right. An invariant IBS CV guarantees that the baroreflex arc behaves consistently and predictably across the full range of physiological states: the brain can rely on a stable gain relationship between blood pressure and heart rate, enabling reliable closed-loop cardiovascular control without having to recalibrate the relationship under every new condition. To test this hypothesis, we had healthy adult volunteers undergo either the cold pressor test or passive orthostatic challenge. Heart rate (HR), systolic blood pressure (SBP), IBS (the regression coefficient of R-R intervals on their respective systolic blood pressures), and the coefficients of variation (CV, i.e. standard deviation ÷ mean value) of each were measured at baseline and during each stress perturbation. During orthostatic challenge, HR rose significantly while SBP fell significantly. Classically, this HR rise is attributed to baroreflex compensation for falling pressure. However, the critical observation is that SBP was not restored to baseline. Instead, it remained substantially reduced while HR stayed persistently elevated and HR CV increased significantly. A system primarily defending a blood pressure set point should augment baroreflex gain and suppress pressure variability; instead mean IBS showed no significant change, SBP CV amplified more than threefold, and IBS CV was unchanged. During the cold pressor test, both HR and SBP rose simultaneously, which is inconsistent with a pressure-defending system that would have suppressed HR in response to the large rise in SBP. IBS CV was also stable across this perturbation while SBP CV amplified dramatically. These findings challenge the classical baroreceptor set-point model and suggest that IBS CV, not blood pressure, is the primary regulated cardiovascular variable.
- 1 October 2025
- Published by American Physiological Society in American Journal of Physiology-Heart and Circulatory Physiology
- Vol. 329 (4) , H880-H888
Chloride/bicarbonate exchange adversely modifies cardiovascular responses to traumatic brain injury
Our findings may lead to a new way to effectively treat the chronic stress, anxiety, and excessive cardiovascular reactivity that frequently follow head injuries, such as sports concussion.
- 1 October 2025
- Published by American Physiological Society in American Journal of Physiology-Heart and Circulatory Physiology
- Vol. 329 (4) , H880-H888
Chloride/bicarbonate exchange adversely modifies cardiovascular responses to traumatic brain injury
Our findings may lead to a new way to effectively treat the chronic stress, anxiety, and excessive cardiovascular reactivity that frequently follow head injuries, such as sports concussion.
- Open Access
- 6 December 2024
- Published by MDPI AG in International Journal of Translational Medicine
- Vol. 4 (4) , 726-739
A Practical Format to Organize Cancer Constellations Using Innate Immune System Biomarkers: Implications for Early Diagnosis and Prognostication
Cancer discovery is directed at the identification of a specific cancer type which allows for specific therapeutic interventions. Background/Objectives: Recently, similar immune checkpoint therapeutics have been applied with success across several cancer types, opening the field for other immune disruptive interventions that have practical applications. Methods: We have discovered an innate immune system (InImS) biomarker that allows for the characterization of allied cancer subtypes and outliers that might aid with diagnosis, treatment, and prognostication. Results: These InImS biomarkers are related to PD-L1 treatment outcomes and can be potentially manipulated by dietary means. Conclusions: The FERAD (ferritin–fecal p87) and absolute neutrophil/lymphocyte (aNLR) ratios are two such InImS biomarkers and we show herein, that they allow for the discovery of diagnosis and prognostication patterns, as demonstrated by this study.
- 6 December 2024
- Published by MDPI AG in International Journal of Translational Medicine
- Vol. 4 (4) , 726-739
Open AccessA Practical Format to Organize Cancer Constellations Using Innate Immune System Biomarkers: Implications for Early Diagnosis and Prognostication
Cancer discovery is directed at the identification of a specific cancer type which allows for specific therapeutic interventions. Background/Objectives: Recently, similar immune checkpoint therapeutics have been applied with success across several cancer types, opening the field for other immune disruptive interventions that have practical applications. Methods: We have discovered an innate immune system (InImS) biomarker that allows for the characterization of allied cancer subtypes and outliers that might aid with diagnosis, treatment, and prognostication. Results: These InImS biomarkers are related to PD-L1 treatment outcomes and can be potentially manipulated by dietary means. Conclusions: The FERAD (ferritin–fecal p87) and absolute neutrophil/lymphocyte (aNLR) ratios are two such InImS biomarkers and we show herein, that they allow for the discovery of diagnosis and prognostication patterns, as demonstrated by this study.
- Open Access
Pathogenic soluble tau peptide disrupts endothelial calcium signaling and vasodilation in the brain microvasculature
The accumulation of the microtubule-associated tau protein in and around blood vessels contributes to brain microvascular dysfunction through mechanisms that are incompletely understood. Delivery of nutrients to active neurons in the brain relies on capillary inositol 1,4,5-triphosphate receptor (IP 3 R)–mediated calcium (Ca 2+ ) signals to direct blood flow. The initiation and amplification of endothelial cell IP 3 R-mediated Ca 2+ signals requires an intact microtubule cytoskeleton. Since tau accumulation in endothelial cells disrupts native microtubule stability, we reasoned that tau-induced microtubule destabilization would impair endothelial IP 3 -evoked Ca 2+ signaling. We tested the hypothesis that tau disrupts the regulation of local cerebral blood flow by reducing endothelial cell Ca 2+ signals and endothelial-dependent vasodilation. We used a pathogenic soluble tau peptide (T-peptide) model of tau aggregation and mice with genetically encoded endothelial Ca 2+ sensors to measure cerebrovascular endothelial responses to tau exposure. T-peptide significantly attenuated endothelial Ca 2+ activity and cortical capillary blood flow in vivo within 120 seconds. Further, T-peptide application constricted pressurized cerebral arteries and inhibited endothelium-dependent vasodilation. This study demonstrates that pathogenic tau alters cerebrovascular function through direct attenuation of endothelial Ca 2+ signaling and endothelium-dependent vasodilation.
Open AccessPathogenic soluble tau peptide disrupts endothelial calcium signaling and vasodilation in the brain microvasculature
The accumulation of the microtubule-associated tau protein in and around blood vessels contributes to brain microvascular dysfunction through mechanisms that are incompletely understood. Delivery of nutrients to active neurons in the brain relies on capillary inositol 1,4,5-triphosphate receptor (IP 3 R)–mediated calcium (Ca 2+ ) signals to direct blood flow. The initiation and amplification of endothelial cell IP 3 R-mediated Ca 2+ signals requires an intact microtubule cytoskeleton. Since tau accumulation in endothelial cells disrupts native microtubule stability, we reasoned that tau-induced microtubule destabilization would impair endothelial IP 3 -evoked Ca 2+ signaling. We tested the hypothesis that tau disrupts the regulation of local cerebral blood flow by reducing endothelial cell Ca 2+ signals and endothelial-dependent vasodilation. We used a pathogenic soluble tau peptide (T-peptide) model of tau aggregation and mice with genetically encoded endothelial Ca 2+ sensors to measure cerebrovascular endothelial responses to tau exposure. T-peptide significantly attenuated endothelial Ca 2+ activity and cortical capillary blood flow in vivo within 120 seconds. Further, T-peptide application constricted pressurized cerebral arteries and inhibited endothelium-dependent vasodilation. This study demonstrates that pathogenic tau alters cerebrovascular function through direct attenuation of endothelial Ca 2+ signaling and endothelium-dependent vasodilation.
- 11 May 2023
- Published by Wolters Kluwer Health in Journal of Trauma and Acute Care Surgery
- Vol. 95 (4) , 542-548
Alpha-methyltyrosine reduces the acute cardiovascular and behavioral sequelae in a murine model of traumatic brain injury
BACKGROUND: Increased catecholamines contribute to heightened cardiovascular reactivity and behavioral deficits after traumatic brain injury (TBI); adrenergic receptor blockade has limited success in reducing adverse sequelae of TBI. Injury-induced increases in the synthesis of catecholamines could contribute to adverse outcomes in TBI. Inhibition of catecholamine synthesis with alpha-methyltyrosine (αMT) could offer a benefit after TBI. METHODS: Original research trial in mice randomized to αMT (50 mg·kg−1·d−1) or vehicle for 1 week after TBI induced by controlled cortical impact. Primary outcomes of cardiovascular reactivity and behavioral deficits were assessed after 1 week. Secondary outcomes included blood brain barrier permeability and quantification of gene transcription whose products determine intraneuronal chloride concentrations, the release of catecholamines, and activation of the sympathetic nervous system. These genes were the alpha-2 adrenergic receptor (“Adra2c”), the sodium-potassium-chloride cotransporter (“Nkcc1”), and the potassium chloride cotransporter (“Kcc2”). We also assessed the effect of TBI and αMT on the neuronal chloride/bicarbonate exchanger (“Ae3”). RESULTS: Traumatic brain injury–induced increases in blood pressure and cardiac reactivity were blocked by αMT. Inhibition of catecholamine synthesis decreased blood brain barrier leakage and improved behavioral outcomes after TBI. Traumatic brain injury diminished the transcription of Adra2c and enhanced expression of Nkcc1 while reducing Kcc2 transcription; αMT prevented the induction of the Nkcc1 by TBI without reversing the effects of TBI on Kcc2 expression; αMT also diminished Ae3 transcription. CONCLUSION: Traumatic brain injury acutely increases cardiovascular reactivity and induces behavioral deficits in an αMT-sensitive manner, most likely by inducing Nkcc1 gene transcription. Alpha-methyltyrosine may prove salutary in the treatment of TBI by attenuating the enhanced expression of Nkcc1, minimizing blood brain barrier leakage, and diminishing central catecholamine and sympathetic output. We also found an unreported relationship between Kcc2 and the chloride/bicarbonate exchanger, which should be considered in the design of trials planned to manipulate central intraneuronal chloride concentrations following acute brain injury.
- 11 May 2023
- Published by Wolters Kluwer Health in Journal of Trauma and Acute Care Surgery
- Vol. 95 (4) , 542-548
Alpha-methyltyrosine reduces the acute cardiovascular and behavioral sequelae in a murine model of traumatic brain injury
BACKGROUND: Increased catecholamines contribute to heightened cardiovascular reactivity and behavioral deficits after traumatic brain injury (TBI); adrenergic receptor blockade has limited success in reducing adverse sequelae of TBI. Injury-induced increases in the synthesis of catecholamines could contribute to adverse outcomes in TBI. Inhibition of catecholamine synthesis with alpha-methyltyrosine (αMT) could offer a benefit after TBI. METHODS: Original research trial in mice randomized to αMT (50 mg·kg−1·d−1) or vehicle for 1 week after TBI induced by controlled cortical impact. Primary outcomes of cardiovascular reactivity and behavioral deficits were assessed after 1 week. Secondary outcomes included blood brain barrier permeability and quantification of gene transcription whose products determine intraneuronal chloride concentrations, the release of catecholamines, and activation of the sympathetic nervous system. These genes were the alpha-2 adrenergic receptor (“Adra2c”), the sodium-potassium-chloride cotransporter (“Nkcc1”), and the potassium chloride cotransporter (“Kcc2”). We also assessed the effect of TBI and αMT on the neuronal chloride/bicarbonate exchanger (“Ae3”). RESULTS: Traumatic brain injury–induced increases in blood pressure and cardiac reactivity were blocked by αMT. Inhibition of catecholamine synthesis decreased blood brain barrier leakage and improved behavioral outcomes after TBI. Traumatic brain injury diminished the transcription of Adra2c and enhanced expression of Nkcc1 while reducing Kcc2 transcription; αMT prevented the induction of the Nkcc1 by TBI without reversing the effects of TBI on Kcc2 expression; αMT also diminished Ae3 transcription. CONCLUSION: Traumatic brain injury acutely increases cardiovascular reactivity and induces behavioral deficits in an αMT-sensitive manner, most likely by inducing Nkcc1 gene transcription. Alpha-methyltyrosine may prove salutary in the treatment of TBI by attenuating the enhanced expression of Nkcc1, minimizing blood brain barrier leakage, and diminishing central catecholamine and sympathetic output. We also found an unreported relationship between Kcc2 and the chloride/bicarbonate exchanger, which should be considered in the design of trials planned to manipulate central intraneuronal chloride concentrations following acute brain injury.
- Open Access
- 1 March 2020
- Published by Elsevier in Metabolism Open
- Vol. 5, 100023
Acetazolamide increases locomotion, exploratory behavior, and weight loss following social stress: A treatment for emotional eating?
- 1 March 2020
- Published by Elsevier in Metabolism Open
- Vol. 5, 100023
Open AccessAcetazolamide increases locomotion, exploratory behavior, and weight loss following social stress: A treatment for emotional eating?
- Open Access
- 7 March 2006
- Published by Wiley in The FASEB Journal
- Vol. 20 (5) , A1177
Chlothalidone inhibits angiotensin‐induced apoptosis in vascular smooth muscle
- 7 March 2006
- Published by Wiley in The FASEB Journal
- Vol. 20 (5) , A1177
Open AccessChlothalidone inhibits angiotensin‐induced apoptosis in vascular smooth muscle